PNC Financial Services Group’s Inhibrx INBX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.88K Hold
41
﹤0.01% 4478
2026
Q1
$2.76K Hold
41
﹤0.01% 4489
2025
Q4
$3.24K Hold
41
﹤0.01% 4391
2025
Q3
$1.38K Buy
41
+10
+32% +$246 ﹤0.01% 4600
2025
Q2
$442 Sell
31
-1,540
-98% -$19.9K ﹤0.01% 4699
2025
Q1
$22K Sell
1,571
-227
-13% -$3.08K ﹤0.01% 3493
2024
Q4
$27.7K Buy
1,798
+852
+90% +$13K ﹤0.01% 3383
2024
Q3
$14.8K Buy
946
+163
+21% +$2.29K ﹤0.01% 3651
2024
Q2
$11.1K Buy
+783
New +$12.2K ﹤0.01% 3734

Other funds holding INBX

PNC Financial Services Group's INBX Position: Q2 2026 in Review

PNC Financial Services Group held its Inhibrx (INBX) position steady in Q2 2026 at 41 shares worth $3.88K. The position accounts for ﹤0.01% of the portfolio, ranked #4478.

PNC Financial Services Group first reported a position in INBX in Q2 2024 and has held it in 9 quarters since. The position peaked at $27.7K in Q4 2024. 46 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • PNC Financial Services Group held 41 shares of Inhibrx worth $3.88K as of Q2 2026.
  • PNC Financial Services Group left its Inhibrx share count unchanged in Q2 2026.
  • Inhibrx made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4478 holding.
  • PNC Financial Services Group first reported a position in Inhibrx in Q2 2024 and has held it in 9 quarters since.
  • PNC Financial Services Group's Inhibrx position peaked at $27.7K in Q4 2024.
  • 46 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.